Afsaneh Mohebbi - PepGen Senior Management

PEPG Stock  USD 4.32  0.08  1.82%   

Executive

Afsaneh Mohebbi is Senior Management of PepGen
Address 321 Harrison Avenue, Boston, MA, United States, 02118
Phone781 797 0979
Webhttps://pepgen.com

PepGen Management Efficiency

The company has return on total asset (ROA) of (0.352) % which means that it has lost $0.352 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6626) %, meaning that it created substantial loss on money invested by shareholders. PepGen's management efficiency ratios could be used to measure how well PepGen manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.58. The current Return On Capital Employed is estimated to decrease to -0.71. At this time, PepGen's Debt To Assets are most likely to slightly decrease in the upcoming years.
PepGen currently holds 20.1 M in liabilities. PepGen has a current ratio of 10.79, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about PepGen's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Alan FuhrmanTyra Biosciences
67
Kelly NeelonVigil Neuroscience
N/A
MD MBACompass Therapeutics
52
Mary FentonCullinan Oncology LLC
60
Eric MBAPureTech Health PLC
N/A
Leah GibsonVigil Neuroscience
N/A
Cindy BerejikianMineralys Therapeutics, Common
N/A
Spencer BallPureTech Health PLC
N/A
Robert TicktinPmv Pharmaceuticals
62
Jessica PMPVigil Neuroscience
N/A
Liz PaganoTyra Biosciences
N/A
Jennifer HuberAN2 Therapeutics
N/A
MD MBAMolecular Partners AG
N/A
Jennifer CPAVigil Neuroscience
49
Minori MDCompass Therapeutics
61
Minji MBAMineralys Therapeutics, Common
N/A
Kendra AdamsC4 Therapeutics
N/A
David GrayVigil Neuroscience
49
Park CPAVigil Neuroscience
N/A
Mr MBAC4 Therapeutics
46
Danielle BradburyMineralys Therapeutics, Common
N/A
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Pepgen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people. PepGen (PEPG) is traded on NASDAQ Exchange in USA. It is located in 321 Harrison Avenue, Boston, MA, United States, 02118 and employs 76 people. PepGen is listed under Biotechnology category by Fama And French industry classification.

Management Performance

PepGen Leadership Team

Elected by the shareholders, the PepGen's board of directors comprises two types of representatives: PepGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PepGen. The board's role is to monitor PepGen's management team and ensure that shareholders' interests are well served. PepGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PepGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
James McArthur, CEO and President
Caroline Godfrey, Founder Member
Afsaneh Mohebbi, Senior Management
Michelle MD, Senior Development
David CFA, Senior Communications
Jaya Goyal, Executive Development
Hayley Parker, Senior Affairs
Sonia DPHIL, VP Operations
Michael Gait, Founder Member
Jennifer Cormier, VP Operations
Mary DeLena, General Secretary
Mary JD, General Secretary
Kyle Breidenstine, VP Controller
Emiko Bryant, Chief Staff
Noel MBA, Chief Officer
Niels Svenstrup, Manufacturing Chemistry

PepGen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PepGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether PepGen is a strong investment it is important to analyze PepGen's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PepGen's future performance. For an informed investment choice regarding PepGen Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PepGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in PepGen Stock please use our How to Invest in PepGen guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PepGen. If investors know PepGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PepGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.98)
Return On Assets
(0.35)
Return On Equity
(0.66)
The market value of PepGen is measured differently than its book value, which is the value of PepGen that is recorded on the company's balance sheet. Investors also form their own opinion of PepGen's value that differs from its market value or its book value, called intrinsic value, which is PepGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PepGen's market value can be influenced by many factors that don't directly affect PepGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PepGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if PepGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PepGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.